Menu Search
Equities

Epigenomics AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ECX:MUN

Epigenomics AG

Actions
  • Price (EUR)0.986
  • Today's Change0.000 / 0.00%
  • Shares traded9.00
  • 1 Year change-3.33%
  • Beta0.9299
Data delayed at least 15 minutes, as of Feb 10 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.

  • Revenue in EUR (TTM)4.00k
  • Net income in EUR-2.76m
  • Incorporated2000
  • Employees3.00
  • Location
    Epigenomics AGZiegelhaeuser Landstrasse 3HEIDELBERG 69120GermanyDEU
  • Phone+49 62 216492487
  • Fax+49 62 216492472
  • Websitehttps://www.epigenomics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.